Welcome to our dedicated page for PAYCHEX SEC filings (Ticker: PAYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Paychex, Inc. filings document formal disclosures for its human capital management business, including quarterly operating results furnished on Form 8-K, credit facility amendments, capital-return authorizations, and governance changes involving directors and senior officers.
The company's proxy materials and annual-meeting reports address board elections, executive compensation votes, auditor ratification, committee matters, and stockholder voting outcomes. Its filings also describe common-stock repurchase authority, revolving credit facilities, covenant changes, and formal reporting for payroll, HCM, HR Solutions, PEO, ASO, benefits, retirement, and insurance services.
Paychex (PAYX) disclosed a director’s equity awards on Form 4. The reporting person acquired 725 shares of common stock at $0, noted as restricted stock units subject to vesting. The filing also reports a new stock option grant for 3,061 shares at $127.52 on 10/15/2025, exercisable 10/15/2026 and expiring 10/14/2035. Following the transaction, 3,951 shares of common stock were beneficially owned directly.
Paychex (PAYX) filed a Form 3 reporting initial beneficial ownership by an officer. As of the event date 10/09/2025, the reporting person, an SVP, HCM, PEO & Insurance, directly owns 6,683 shares of Common Stock.
Table II lists stock options for Common Stock as follows: 6,775 shares at $119.72 exercisable on 01/15/2025 expiring 01/14/2034; 13,192 shares at $121.63 exercisable on 07/15/2025 expiring 07/14/2034; and 11,813 shares at $140.68 exercisable on 07/15/2026 expiring 07/14/2035. The filing indicates direct ownership and was signed by an attorney-in-fact.
Paychex (PAYX) reported an insider equity award on a Form 4. A director acquired 725 shares of common stock on 10/15/2025 at $0, noted as an award of restricted stock units subject to vesting under the Amended and Restated 2002 Stock Incentive Plan. Following the transaction, the insider beneficially owned 20,504 shares, held directly.
The filing also lists a new stock option grant for 3,061 shares at an exercise price of $127.52 on 10/15/2025, exercisable 10/15/2026 and expiring 10/14/2035. Additional previously granted options with various strike prices and expirations remain outstanding.
Paychex (PAYX) — Form 4 insider activity: A company director reported equity awards dated 10/15/2025. The filing shows 725 shares of common stock acquired at $0, reflecting settlement of restricted stock units under the Amended and Restated 2002 Stock Incentive Plan. Following this, beneficial ownership stands at 67,364 shares, held directly.
The director also reported a new stock option grant for 3,061 shares at an exercise price of $127.52, granted on 10/15/2025, exercisable starting 10/15/2026 and expiring on 10/14/2035. The filing lists additional previously granted options with exercise prices and expirations on a rolling schedule.
Paychex, Inc. (PAYX) filed a Form 4 showing a director received an equity grant on 10/15/2025. The filing reports the award of 725 restricted stock units at a price of $0, pursuant to the Amended and Restated 2002 Stock Incentive Plan.
The director also received a new stock option for 3,061 shares with an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035. Following these transactions, the director beneficially owned 2,800 shares directly. The filing also lists previously awarded options, including 5,082 at $120.86 (expiring 07/14/2033), 3,351 at $121.63 (expiring 07/14/2034), and 670 at $140.68 (expiring 07/14/2035).
Paychex (PAYX) Form 4: A director reported equity awards on 10/15/2025. The filing shows an award of 725 shares of common stock at a price of $0, noted as restricted stock units subject to vesting. Following this, 889 shares were beneficially owned directly, and 23,758 shares were beneficially owned indirectly through the Joseph G. Doody Revocable Living Trust. A stock option for 3,061 shares was granted at an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035.
Paychex (PAYX) reported an insider transaction by its President and CEO. On 10/15/2025, the executive disposed of 624 shares of common stock at $127.52 per share, coded “F”.
According to the footnote, the shares were withheld to satisfy tax obligations arising from the vesting of restricted stock units. Following the transaction, the executive directly holds 81,131 shares of Paychex common stock.
Paychex (PAYX) reported insider activity. A reporting person who is a Director and Chairman received 855 restricted stock units on 10/15/2025 at a price of $0 under the Amended and Restated 2002 Stock Incentive Plan. The person also received a stock option for 3,607 shares with an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035.
Following these transactions, the filer reported 426,324.3318 shares beneficially owned, held directly. The filing also lists previously granted option awards with various exercise prices and expiration dates.
Paychex (PAYX) reported an insider Form 4 for a company officer (VP, Controller & Treasurer). On 10/15/2025, the officer disposed of 38 shares of common stock at $127.52 under code F, reflecting shares withheld to cover taxes from restricted stock units vesting. Following this transaction, the officer beneficially owns 5,389 shares directly.
The filing also lists outstanding stock options, including 7,310 options at an exercise price of $140.68 (exercisable 07/15/2026; expiration 07/14/2035).
Paychex Inc. (PAYX) director reported equity awards. On 10/15/2025, the insider acquired 725 shares of common stock at $0, described as an award of restricted stock units subject to vesting. Following this, the insider beneficially owned 8,254 shares directly. The filing also shows a new stock option grant for 3,061 shares at an exercise price of $127.52, first exercisable on 10/15/2026 and expiring on 10/14/2035, alongside previously granted options with various terms.